Actively Recruiting
Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Advanced Non-HRD-Positive Ovarian Cancer Compared to Standard Care
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-29
802
Participants Needed
11
Research Sites
135 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating new treatment options for advanced ovarian cancer, fallopian tube cancer, and primary peritoneal cancer that are not positive for homologous recombination deficiency non-HRD-positive. The study aims to find out if maintenance treatment with raludotatug deruxtecan R-DXd, a targeted therapy, with or without bevacizumab, can help patients live longer without their cancer worsening compared to the standard care options after initial surgery and platinum-based chemotherapy. Participants will be randomly assigned to receive intravenous R-DXd with or without bevacizumab, or to standard care which includes bevacizumab alone or observation. R-DXd and bevacizumab will be given through IV infusions with bevacizumab dosed at 15 mgkg every 3 weeks for up to 22 cycles, and treatment continuing for up to 2 years or until disease progression or unacceptable side effects occur. During the study, participants will have regular visits for treatment and monitoring over several years. Researchers will assess progression-free survival and overall survival up to approximately 4 to 5.5 years. They will also monitor quality of life, abdominal and gastrointestinal symptoms, and record any adverse events or treatment discontinuations. The study is sponsored by Merck Sharp & Dohme LLC and involves a parallel, randomized, single-blind design.
CONDITIONS
Brief Title
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here